

14<sup>th</sup> March, 2026

Dear REMAP-CAP participating sites,

**RE: REMAP-CAP Influenza Antiviral Domain**

I am writing to inform you of a decision that has been made by the REMAP-CAP International Trial Steering Committee (ITSC) in response to communication from the Data and Safety Monitoring Board (DSMB).

In the most recent adaptive analysis, **the 5-day oseltamivir intervention and the 10-day oseltamivir intervention of the Influenza Antiviral Domain reached a statistical trigger for inferiority** when compared to the other interventions in the Severe Illness Severity State (i.e., critically ill patients). The unanimous recommendation of the DSMB was that these two interventions be closed for randomisation, and the ITSC has accepted this recommendation.

Given the nature of this signal, which suggests potential for harm of oseltamivir, the REMAP-CAP ITSC has decided to also pause enrolment to this domain in all States and Stratum, until we more fully understand the implications of these results for the other interventions in this domain. This has been implemented within the REMAP-CAP eligibility system at all sites, and enrolment to this domain is now paused.

Any patients currently allocated to an intervention containing oseltamivir should have this treatment discontinued.

We will work to analyse and report these findings as soon as possible and request that you only share this information with relevant clinical staff.

On behalf of the REMAP-CAP ITSC we would like to thank the DSMB and the Statistical Analysis Committee for their vital work in ensuring the safety of patients enrolled in REMAP-CAP. We would also like to sincerely thank all investigators, research coordinators, participants and their families who continue to support REMAP-CAP and the generation of evidence for the treatment of influenza and severe respiratory tract infections.

If you have any questions about any of the above, please don't hesitate to contact me, or your regional coordinators.

Sincerely,



Dr Srinivas Murthy  
Chair, REMAP-CAP International Trial Steering Committee  
Chair, Influenza Antiviral Domain-Specific Working Group  
Email: [Srinivas.Murthy@cw.bc.ca](mailto:Srinivas.Murthy@cw.bc.ca)